StageBio, a leading provider of GLP-compliant histology, pathology, image analysis and archiving services for both preclinical and clinical research, is pleased to welcome Shehnaz Kataria to the executive team as Chief Financial Officer.

As Chief Financial Officer, Shehnaz will drive strategic company initiatives, oversee StageBio’s financial strategy, and manage relationships with key partners and stakeholders. 

Shehnaz joins StageBio from Prolytix, a contract research organization with protein chemistry expertise, where she was Chief Financial and People Officer. She also brings over two decades of varied financial and operational leadership experience from companies such as LGC and Saint-Gobain.

“Shehnaz’s history of implementing progressive growth strategies will be a pivotal and valuable asset to the StageBio team,” shares David Bruning, President/CEO of StageBio. “Her ability to influence positive change combined with her strong financial acumen will continue to position StageBio for growth and drive success for our clients.”

Join us in welcoming Shehnaz Kataria to the StageBio team!

Interested in working with StageBio? Learn more about us here.

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for the biopharmaceutical, medical device, academic, government and contract research industries. The company operates three GLP laboratories as well as two GLP specimen archiving facilities in the U.S. and Europe, with substantial continued investment in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 25 board-certified veterinary pathologists and more than 100 scientific personnel on staff supporting our unified commitment to quality, scientific integrity and client satisfaction. Learn more at www.stagebio.com.